• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Amalgam RX Acquires Adaptive, Conversational, Artificial Intelligence (AI) Assets

Share:

May 26, 2021

Amalgam Rx, Inc., the leader in connecting healthcare providers and life sciences companies through a SaaS-enabled digital marketplace and product platform is announcing the acquisition of the assets of Geetha, LLC, an adaptive, conversational AI company. The acquisition bolsters Amalgam’s data science assets, which already include more than 6 billion longitudinal data points on millions of patients cared for across Amalgam’s technology platforms.

Founded in 2014, Geetha boasts a collection of AI models that target the psychosocial and behavioral understanding of stakeholders in the healthcare ecosystem; by establishing learning algorithms to support intervention frameworks, Geetha delivers engaging behavior-change-tailored content using cutting edge Natural Language Understanding and Reinforcement Learning. With this transaction, Amalgam acquires Geetha’s turnkey psychosocial engine (personality, moods, motivators, etc.) in 40 languages, algorithms to collect contextual data via chat, AI-based chat model and platform to create low-no code virtual personalized agents, motivational content, common sense ontology for a rich understanding of a user’s life, and learning algorithms to respond to interactions and improve intervention framework. Geetha’s founder, Bharath Sudharsan, will join the Amalgam executive team as its chief data scientist and head of AI.

“Next-gen AI can deeply understand, empathize, and adapt to each person, almost like a real human friend, with the added benefits of 24/7 availability and expertly curated and safe feedback within a judgment-free space. Every time a patient connects, its rapport, relationship, and level of support can get so much better. When we combine this new AI with Amalgam’s impressive clinical, technology, and regulatory platform/capabilities, it can lead to a deeper level of empathetic engagement, which, in turn, can affect lasting change and outcomes,” said Bharath Sudharsan, newly appointed chief data scientist and head of AI of Amalgam Rx.

“The future of digital health is in delivering highly personalized, scalable, and engaging interventions that learn and adapt over time based on an individual’s needs; big data and AI form the foundation of this future. We’re thrilled to acquire Geetha’s AI assets and have Bharath join our team,” said Ryan Sysko, chief executive officer and founder of Amalgam Rx.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Winning digital health solutions of the future will seek to treat the human and not just the patient. Incorporating empathy into patient management is a highly effective and powerful tool to build trust and enhance patient outcomes. It’s an important frontier in the digital health space as emerging AI technologies enable a deeper level of understanding and connection with people,” said Suzanne Clough, MD, chief medical officer of Amalgam Rx.

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Afya Limited Announces Entering into of Purchase Agreement for the Acquisition of Faculdade de Ensino Superior da Amazônia ReunidaAfya Limited Announces Entering into of Purchase Agreement for the Acquisition of Faculdade de Ensino Superior da Amazônia Reunida
  • Podimetrics Secures $45M for SmartMat to Prevent Diabetic Amputations in High-Risk PatientsPodimetrics Secures $45M for SmartMat to Prevent Diabetic Amputations in High-Risk Patients
  • Dr. Reddy’s Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, TennesseeDr. Reddy’s Laboratories Announces the Sale of Its Antibiotic Manufacturing Site and Its Related Assets in Bristol, Tennessee
  • Thomas H. Lee Partners and Frazier Healthcare Partners Acquire AdareThomas H. Lee Partners and Frazier Healthcare Partners Acquire Adare
  • UnitedHealthcare app Gives Members on-Demand Access to Telehealth ServicesUnitedHealthcare app Gives Members on-Demand Access to Telehealth Services
  • How Will Blockchain Impact Healthcare? Tech Leaders Weigh InHow Will Blockchain Impact Healthcare? Tech Leaders Weigh In
  • PM-STIAC identifies genomic data, AI & quantum computing in healthcare to spur innovations & emulate global counterpartsPM-STIAC identifies genomic data, AI & quantum computing in healthcare to spur innovations & emulate global counterparts
  • Shineco, Inc. Intends to Acquire Biotechnology Company to Jointly Develop Rapid-acting Antidepressant Natural Innovative MedicineShineco, Inc. Intends to Acquire Biotechnology Company to Jointly Develop Rapid-acting Antidepressant Natural Innovative Medicine

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications